OTX-TKI (Axpaxli) offers a novel approach for wet macular degeneration with sustained drug release up to 9 months via a hydrogel platform. Two phase 3 trials, SOL-1 and SOL-R, evaluate Axpaxli's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback